Skip to main content Accessibility help
×
Home

Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms

  • Celia J. A. Morgan (a1), Emma Page (a2), Carola Schaefer (a3), Katharine Chatten (a1), Amod Manocha (a3), Sumit Gulati (a2), H. Valerie Curran (a2), Brigitta Brandner (a2) and F. Markus Leweke (a2)...

Summary

Anandamide is a ligand of the endocannabinoid system. Animals show a depletion following repeated Δ9-tetrahydrocannabinol (THC) administration but the effect of cannabis use on central nervous system levels of endocannabinoids has not been previously examined in humans. Cerebrospinal fluid (CSF) levels of the endocannabinoids anandamide, 2-arachidonoylglycerol (2-AG) and related lipids were tested in 33 volunteers (20 cannabis users). Lower levels of CSF anandamide and higher levels of 2-AG in serum were observed in frequent compared with infrequent cannabis users. Levels of CSF anandamide were negatively correlated with persisting psychotic symptoms when drug-free. Higher levels of anandamide are associated with a lower risk of psychotic symptoms following cannabis use.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms
      Available formats
      ×

Copyright

Corresponding author

Celia Morgan, Clinical Psychopharmacology Unit, University College London, Gower St, London WC1E 6BT, UK. Email: c.morgan@ucl.ac.ukx

Footnotes

Hide All

Declaration of interest

None.

Footnotes

References

Hide All
1 Leweke, FM, Giuffrida, A, Wurster, U, Emrich, HM, Piomelli, D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10: 1665–9.
2 Giuffrida, A, Leweke, FM, Gerth, CW, Schreiber, D, Koethe, D, Faulhaber, J, et al Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29: 2108–14.
3 Koethe, D, Giuffrida, A, Schreiber, D, Hellmich, M, Schultze-Lutter, F, Ruhrmann, S, et al Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 2009; 194: 371–2.
4 Leweke, FM. Anandamide dysfunction in prodromal and established psychosis. Curr Pharm Des 2012; 18: 5188–93.
5 Di Marzo, V, Berrendero, F, Bisogno, T, Gonzalez, S, Cavaliere, P, Romero, J, et al Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J Neurochem 2000; 74: 1627–35.
6 Leweke, FM, Giuffrida, A, Koethe, D, Schreiber, D, Nolden, BM, Neatby, MA, et al Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 2007; 94: 2936.
7 Morgan, CJA, Schafer, G, Freeman, TP, Curran, HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 2010; 197: 285–90.
8 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
9 Mason, OJ, Morgan, CJ, Stefanovic, A, Curran, HV. The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophr Res 2008; 103: 138–42.
10 Bossong, MG, van Berckel, BN, Boellaard, R, Zuurman, L, Schuit, RC, Windhorst, AD, et al Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009; 34: 759–66.
11 Hill, MN, Miller, GE, Ho, WS, Gorzalka, BB, Hillard, CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008; 41: 4853.
Type Description Title
PDF
Supplementary materials

Morgan et al. supplementary material
Supplementary Figure S1

 PDF (27 KB)
27 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms

  • Celia J. A. Morgan (a1), Emma Page (a2), Carola Schaefer (a3), Katharine Chatten (a1), Amod Manocha (a3), Sumit Gulati (a2), H. Valerie Curran (a2), Brigitta Brandner (a2) and F. Markus Leweke (a2)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *